Search results
30 mar 2022 · The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
We enrolled 654 patients in the BRAVE-AA1 trial and 546 in...
- Images in Clinical Medicine Primary Cutaneous Blastomycosis A. Alhatem and K.C. Smith
A 53-year-old landscaper presented with a 4-month history of...
- Perspective Real-World Evidence — Where Are We Now J. Concato and J. Corrigan-Curay
Notwithstanding ongoing confusion over the concepts of...
- Clinical Practice Nonspecific Low Back Pain A. Chiarotto and B.W. Koes
Nonspecific low back pain is diagnosed by ruling out other...
- Editorial Baricitinib in Alopecia Areata A. Messenger and M. Harries
Scalp hair regrowth is associated with improvements in...
- Clinical Problem-Solving Looking Back L. Glick and Others
On examination, the temperature was 36.1°C, the blood...
- Correspondence Dec 15, 2022 Ivermectin Treatment for Covid-19
Accelerating COVID-19 Therapeutic Interventions and Vaccines...
- Editorial Audio Interview
In this audio interview conducted on May 2, 2022, the...
- Original Article Two Phase 3 Trials of Baricitinib for Alopecia Areata B. King and Others
14 gru 2022 · Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Naggie S. Ivermectin for treatment of mild-to-moderate COVID-19 in the outpatient setting: a...
We included randomized controlled trials that evaluated patients with confirmed COVID-19, or those with suspicion of COVID-19 by clinical symptoms and imaging findings, which compared systemic ivermectin with placebo, no treatment, standard care (as defined by the researchers in the individual studies) or other drugs for COVID-19 treatment ...
Methods: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. Enrolment was done between 1st August and 31st October 2020.
26 lip 2021 · For patients with COVID-19 who are, or may become, candidates for dexamethasone, it is reasonable to consider presumptive treatment with Ivermectin for moderate-to high-risk patients not previously tested or treated for Strongyloides.
22 lip 2024 · This study aimed to assess the efficacy and safety of oral ivermectin in hospitalized patients with mild to moderate Covid-19. A double-blind, randomized placebo-controlled clinical trial was conducted among RT-PCR-confirmed, adults, hospitalised within the first four days of symptoms.
16 lut 2021 · The study was aimed to explore the association between ivermectin prophylaxis and the development of SARS-CoV-2 infection among healthcare workers. Methods: A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020.
